(Q42491225)

English

Prostatic invasive adenocarcinoma. Effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of proliferating cell nuclear antigen (PCNA).

scientific article published in December 1993

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Prostatic invasive adenocarcinoma. Effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of proliferating cell nuclear antigen (PCNA). (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

1 reference

based on heuristic

inferred from title

author name string

Magi Galluzzi C

1

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Montironi R

2

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Giannulis I

3

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Diamanti L

4

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Scarpelli M

5

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Muzzonigro G

6

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Polito M

7

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

publication date

1 December 1993

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Pathology, Research and Practice

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

189

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

1154-1160

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Cell proliferation in prostatic adenocarcinoma: in vitro measurement by 5-bromodeoxyuridine incorporation and proliferating cell nuclear antigen expression

1 reference

https://api.crossref.org/works/10.1016%2FS0344-0338%2811%2980838-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase

1 reference

https://api.crossref.org/works/10.1016%2FS0344-0338%2811%2980838-1

7 January 2021

based on heuristic

inferred from DOI database lookup

PCNA/cyclin expression and BrdU uptake define different subpopulations in different cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0344-0338%2811%2980838-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of neoadjuvant hormonal manipulation in localized prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0344-0338%2811%2980838-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Idiopathic Resistance to Luteinizing Hormone-Releasing Hormone Analogue in a Patient with Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0344-0338%2811%2980838-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathologic changes associated with androgen deprivation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0344-0338%2811%2980838-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Application of the Monoclonal Antibody Ki-67 on Prostate Biopsies to Assess the Proliferative Cell Fraction of Human Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0344-0338%2811%2980838-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Growth fractions in human prostatic carcinoma determined by Ki-67 immunostaining

1 reference

https://api.crossref.org/works/10.1016%2FS0344-0338%2811%2980838-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of growth fraction in advanced prostate cancer by Ki-67 immunostaining and its relationship to the time to tumor progression after hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0344-0338%2811%2980838-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitory effects of analogs of luteinizing hormone-releasing hormone and somatostatin on pancreatic cancers in hamsters. Events that accompany tumor regression

1 reference

https://api.crossref.org/works/10.1016%2FS0344-0338%2811%2980838-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. A histopathologic and immunohistochemical study.

1 reference

https://api.crossref.org/works/10.1016%2FS0344-0338%2811%2980838-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0344-0338%2811%2980838-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Histologic changes in the rat prostate cancer model after treatment with somatostatin analogs and D-Trp-6-LH-RH

1 reference

https://api.crossref.org/works/10.1016%2FS0344-0338%2811%2980838-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0344-0338(11)80838-1

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42491225&oldid=1572092975"